Ovarian Cancer: new victory for Johnson & Johnson

News 21 October, 2017
  • QMI agency

    Saturday, October 21, 2017 10:54

    UPDATE
    Saturday, October 21, 2017 10:54

    Look at this article

    LOS ANGELES | Condemned to pay millions to a woman who blamed the company after having developed ovarian cancer, the american giant Johnson & Johnson has just won a battle, and second this week.

    The superior Court of California decided Friday to Johnson & Johnson by cancelling the payment of 417 million US $ of damages and in ordering a new trial, the judge considered that the arguments of the complainant were not convincing enough.

    The complainant of 63 years, Eva Echeverria, was to receive 347 million US $ in punitive damages and US $ 70 million in compensatory damages.

    She alleged that the products of talc from Johnson & Johnson, including the famous baby powder, have caused the development of his disease. A jury had given him reason, last August. Ms. Echeverria believes that the company did not inform properly consumers of the risks posed by its products.

    Earlier this week, an appellate court of Missouri had also reversed the decision that sentenced the pharmaceutical giant to pay $ 72 million US to Jacqueline Fox, a woman who, however, died at 62 years old, died of cancer of the ovaries.

    The pharmaceutical of New Brunswick, New Jersey, had appealed all their convictions. The company denies that there is any link between its products based on talc and the development of ovarian cancer.

    Johnson & Johnson submits, studies to support, that its products based on talc is not carcinogenic. In particular, the Food and Drug Administration of the United States does not consider that there is a proven association between cancer and cosmetics to a base of talc.

    In a release, the company has said to be satisfied with the decision of Friday, according to the Agency Bloomberg. For his part, Mark Robinson, counsel for the complainant Eva Echeverria, has promised to appeal this new decision.